Notably, in ovarian cancer, EpCAM-positive cancer cells were highly present in malignant ascites of recurrent ovarian cancer patients [42, 44], and the high prevalence of EpCAM-positive cancer cells qualifies this antigen as a prospective target for catumaxomab therapy. This evidence concerns the gene EPCAM and ovarian carcinoma.